Neurocrine reports progress of insomnia drug.

Unveils the results of Neurocrine Biosciences Inc.'s phase III clinical trial with two doses of the immediate release formulation of indiplon designated for the treatment of chronic insomnia. Measurement of the latency to sleep onset of patients; Response of elderly patients taking indiplon; Demonstration of the safety and efficacy of indiplon in treating elderly patients who experience chronic insomnia.